RecruitingNCT04654208
Swedish Ibrance Registries Insights (SIRI)
Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)
Sponsor
Pfizer
Enrollment
1,500 participants
Start Date
Dec 15, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
- Age ≥18 years at index date
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGpalbociclib
patients on palbociclib combination treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04654208
Related Trials
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
NCT070671381 location
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
NCT068782485 locations
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT0346395413 locations
Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery
NCT046698731 location